Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study

This study investigated the safety and efficacy of obinutuzumab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (G-CHOP) in patients with advanced diffuse large B-cell lymphoma (DLBCL) and explored the impact of cell-of-origin (COO) on patient outcomes. Patients (N = 100) received ob...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Leuk Lymphoma
Main Authors: Sharman, Jeff P., Forero-Torres, Andres, Costa, Luciano J., Flinn, Ian W., Inhorn, Lowell, Kelly, Kevin, Bessudo, Alberto, Fayad, Luis E., Kaminski, Mark S., Evens, Andrew M., Flowers, Christopher R., Sahin, Deniz, Mundt, Kirsten E., Sandmann, Thomas, Fingerle-Rowson, Günter, Vignal, Charlotte, Mobasher, Mehrdad, Zelenetz, Andrew D.
Format: Artigo
Sprog:Inglês
Udgivet: 2018
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6445782/
https://ncbi.nlm.nih.gov/pubmed/30277102
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2018.1515940
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker